The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | ABBV-400 in patients with advanced EGFR WT non-squamous NSCLC: results from a Phase I study
Mariana Brandão, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses findings from a Phase I study (NCT05029882) of ABBV-400, an antibody-drug conjugate (ADC) targeting c-Met, which is often overexpressed in non-small cell lung cancer (NSCLC).The Phase I study evaluated its safety and efficacy in patients with EGFR wild-type NSCLC that had progressed after prior treatments. In 48 patients, ABBV-400 demonstrated a tolerable safety profile with common side effects including anemia, nausea, and neutropenia. The preliminary objective response rate (ORR) showed potential antitumor activity and warrants further study in NSCLC subtypes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
